结缔组织病患者胸腹主动脉及弓部动脉瘤的分支/开窗支架腔内修复
单中心回顾2004–2015年17例结缔组织病合并胸腹主动脉或弓部动脉瘤、不适合开放手术的患者,采用开窗和/或分支支架腔内修复。技术成功率100%,无早期死亡、脊髓缺血、卒中或夹层进展;中位随访3.4年,35%瘤囊缩小、65%稳定,无瘤囊或密封区扩大及开放转换,1例再干预。
要点
- 结缔组织病合并TAAA或弓部动脉瘤、不适合开放手术者,开窗/分支支架中短期结果良好。
- 技术成功率100%,无早期死亡、脊髓缺血、卒中或夹层进展。
- 需终身密切监测,应在同时具备开放和腔内主动脉手术经验的中心进行。
核心结论
- 对于不适合开放手术的结缔组织病合并胸腹主动脉及弓部动脉瘤患者,开窗和/或分支支架腔内修复的中期结果良好,可考虑应用。
研究设计与样本
- 单中心高容量中心回顾性研究,纳入2004–2015年17例结缔组织病患者(16例TAAA,1例弓部),均不适合开放手术;排除破裂动脉瘤和急性主动脉夹层,但包括慢性夹层。
主要发现
- 技术成功率100%,无早期死亡、脊髓缺血、卒中或进一步夹层。
- 术后肾功能恶化3例(18.8%),无需血液透析。
- 平均随访3.4年(0.3–7.4),瘤囊缩小6/17(35%),稳定11/17(65%),无瘤囊或密封区扩大,无开放转换。
- 1例术后2年因双侧肾动脉闭塞再干预(纤溶成功);1例II型内漏(腰动脉)监测中,1例III型内漏(左肾支架)自行封闭。
- 1例术后2年死于非主动脉原因(心内膜炎)。
临床怎么用
- 结缔组织病合并TAAA或弓部动脉瘤且不适合开放手术者,可考虑开窗和/或分支支架腔内修复。
- 术后需终身密切监测,应在同时具备开放和腔内主动脉手术经验的中心进行,以便早期识别腔内治疗失败并进一步处理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prophylactic open surgery is the standard practice in patients with connective tissue and thoracoabdominal aortic aneurysm (TAAA) and aortic arch disease. Branched and fenestrated devices offer a less invasive alternative but there are concerns regarding the durability of the repair and the effect of the stent graft on the fragile aortic wall. The aim of this study is to evaluate mid-term outcomes of fenestrated and/or branched endografting in patients with connective tissue disease. METHODS: All patients with connective tissue disease who underwent TAAA or arch aneurysm repair using a fenestrated and/or branched endograft in a single, high-volume center between 2004 and 2015 were included. Ruptured aneurysms and acute aortic dissections were excluded from this study, but not chronic aortic dissections. RESULTS: In total, 427 (403 pararenal and TAAAs, and 24 arch aneurysms) endovascular interventions were performed during the study period. Of these, 17 patients (4%) (16 TAAAs, 1 arch) had connective tissue disease. All patients were classified as unfit for open repair. The mean age was 51 ± 8 years. Thirteen patients with TAAA were treated with a fenestrated, 1 with a branched, and 2 with a combined fenestrated/branch device. A double inner branch device was used to treat the arch aneurysm. The technical success rate was 100% with no incidence of early mortality, spinal cord ischemia, stroke, or further dissection. Postoperative deterioration in renal function was seen in 3 patients (18.8%) and no hemodialysis was required. The mean follow-up was 3.4 years (0.3-7.4). Aneurysm sac shrinkage was seen in 35% of patients (6/17) and the sac diameter remained stable in 65% of patients (11/17). No sac or sealing zone enlargement was observed in any of the patients and there were no conversions to open repair. Reintervention was required in 1 patient at 2 years for bilateral renal artery occlusion (successful fibrinolysis). One type II endoleak (lumbar) is under surveillance and 1 type III (left renal stent) sealed spontaneously. One patient died at 2 years after the procedure from nonaortic causes (endocarditis). CONCLUSIONS: The favorable mid-term outcomes in this series that demonstrate fenestrated and/or branched endografting should be considered in patients with connective tissue and TAAA and aortic arch disease, which are considered unfit for open surgery. All patients require close lifetime surveillance at a center specializing in aortic surgery, with sufficient experience in both open and endovascular aortic surgery, so that if endovascular treatment failure occurs it can be recognized early and further treatment offered.
引用
- Clough RE, Martin-Gonzalez T, Van Calster K, et al. Endovascular Repair of Thoracoabdominal and Arch Aneurysms in Patients with Connective Tissue Disease Using Branched and Fenestrated Devices. Ann Vasc Surg. 2017. PMID: 28546044. doi:10.1016/j.avsg.2017.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。